Acalabrutinib approved for use in the EU for chronic lymphocytic leukaemia

The European Commission has approved acalabrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, on the basis of the ELEVATE-TN (previously untreated disease) and ASCEND (relapsed or refractory disease) trials.

Source:

PharmaTimes